A Randomized, Open Label, Single-Centre, Single-Dose, 4-Period, 4-Treatment Cross-over Study to Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) Under Fasting and Fed Conditions, to Compare to Intravenous Arsenic Trioxide, and to Evaluate Interaction With Calcium Carbonate in Patients With Acute Promyelocytic Leukemia.
Latest Information Update: 05 Aug 2025
At a glance
- Drugs Arsenic trioxide (Primary) ; Calcium carbonate
- Indications Acute promyelocytic leukaemia
- Focus Pharmacokinetics
- Sponsors SDK Therapeutics
Most Recent Events
- 18 Jul 2025 Status changed from recruiting to completed.
- 06 May 2025 New trial record